Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression

Pigment Cell and Melanoma Research

Volumn 24, Issue 3, 2011, Pages 490-503

  Soo, Julia K ^a   Mackenzie Ross, Alastair D ^a,e   Kallenberg, David M ^a   Milagre, Carla ^b   Heung Chong, W ^a   Chow, Jade ^a   Hill, Lucy ^c   Hoare, Stacey ^d   Collinson, Rebecca S ^a   Hossain, Mehnaz ^a   Keith, W Nicol ^d   Marais, Richard ^b   Bennett, Dorothy C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c St Georges NHS Hospital Trust Tooting   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cell senescence; Crisis; Immortalization; Nevus; Primary melanoma; Radial growth phase

Indexed keywords

BETA GALACTOSIDASE; PROTEIN P16; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ANAPHASE; ANEUPLOIDY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME; CONTROLLED STUDY; GROWTH CURVE; HETEROCHROMATIN; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MELANOMA; NEVUS CELL; ONCOGENE; PIGMENTED NEVUS; PROTEIN EXPRESSION; SENESCENCE; TELOMERE;

ANAPHASE; ANEUPLOIDY; CELL AGING; HUMANS; MELANOMA; NEOPLASM PROTEINS; NEVUS, PIGMENTED; TELOMERE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79956054057     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00850.x     Document Type: Article

References (69)

1. d'Adda di Fagagna, F. (2008). Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8, 512-522.
2. Artandi, S.E., and DePinho, R.A. (2010). Telomeres and telomerase in cancer. Carcinogenesis 31, 9-18.
3. Atkinson, S.P., Hoare, S.F., Glasspool, R.M., and Keith, W.N. (2005). Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 65, 7585-7590.
4. Barradas, M., Anderton, E., Acosta, J.C. et al. (2009). Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23, 1177-1182.
5. Bennett, D.C. (2003). Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063-3069.
6. Bennett, D.C. (2008). How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27-38.
7. Bennett, D.C., and Medrano, E.E. (2002). Molecular regulation of melanocyte senescence. Pigment Cell Res. 15, 242-250.
8. Bennett, D.C., Bridges, K., and McKay, I.A. (1985). Clonal separation of mature melanocytes from premelanocytes in a diploid human cell strain: spontaneous and induced pigmentation of premelanocytes. J. Cell Sci. 77, 167-183.
9. Bennett, D.C., Cooper, P.J., and Hart, I.R. (1987). A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 39, 414-418.
10. Bilsland, A.E., Hoare, S., Stevenson, K. et al. (2009). Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE 4, e6459.
11. Bond, J.A., Haughton, M.F., Rowson, J.M., Smith, P.J., Gire, V., Wynford-Thomas, D., and Wyllie, F.S. (1999). Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis. Mol. Cell. Biol. 19, 3103-3114.
12. Carvalho, L., Lipay, M., Belfort, F., Santos, I., Andrade, J., Haddad, A., Brunstein, F., and Ferreira, L. (2006). Telomerase activity in prognostic histopathologic features of melanoma. J. Plast. Reconstr. Aesthet. Surg. 59, 961-968.
13. Chen, Q.M. (2000). Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann. N Y Acad. Sci. 908, 111-125.
14. Chin, K., de Solorzano, C.O., Knowles, D. et al. (2004). In situ analyses of genome instability in breast cancer. Nat. Genet. 36, 984-988.
15. Cichowski, K., and Hahn, W.C. (2008). Unexpected pieces to the senescence puzzle. Cell 133, 958-961.
16. Clark, W.H., Elder, D.E., Guerry, D., Braitman, L.E., Trock, B.J., Schultz, D., Synnestvedt, M., and Halpern, A.C. (1989). Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81, 1893-1904.
17. Collado, M., Gil, J., Efeyan, A. et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436, 642.
18. Collado, M., Blasco, M.A., and Serrano, M. (2007). Cellular senescence in cancer and aging. Cell 130, 223-233.
19. Cotter, M.A., Florell, S.F., Leachman, S.A., and Grossman, D. (2007). Absence of senescence-associated β-galactosidase activity in human melanocytic nevi in vivo. J. Invest. Dermatol. 127, 2469-2471.
20. CR-UK Statistical Information Team. CancerStats. CR-UK Online News and Resources. 2010.
21. DePinho, R.A., and Polyak, K. (2004). Cancer chromosomes in crisis. Nat. Genet. 36, 932-934.
22. Dimri, G.P., Lee, X., Basile, G. et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367.
23. Feldser, D.M., and Greider, C.W. (2007). Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461-469.
24. Gisselsson, D., and Höglund, M. (2005). Connecting mitotic instability and chromosome aberrations in cancer--can telomeres bridge the gap? Semin. Cancer Biol. 15, 13-23.
25. Gisselsson, D., Jonson, T., Petersen, A., Strombeck, B., Dal Cin, P., Hoglund, M., Mitelman, F., Mertens, F., and Mandahl, N. (2001). Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc. Natl. Acad. Sci. USA 98, 12683-12688.
26. Glaessl, A., Bosserhoff, A.K., Buettner, R., Hohenleutner, U., Landthaler, M., and Stolz, W. (1999). Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch. Dermatol. Res. 291, 81-87.
27. Gray-Schopfer, V.C., and Bennett, D.C. (2006). The genetics of melanoma. In The Pigmentary System. Physiology and Pathophysiology, J.J., Nordlund, R.E., Boissy, V.J. Hearing, R.A. King, W.S. Oetting, and J.P. Ortonne, eds. 2 edn. (New York: Blackwell Publishing), pp. 472-488.
28. Gray-Schopfer, V.C., Cheong, S.C., Chow, J., Moss, A., Abdel-Malek, Z.A., Marais, R., Wynford-Thomas, D., and Bennett, D.C. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496-505.
29. Ha, L., Ichikawa, T., Anver, M. et al. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl Acad. Sci. USA 104, 10968-10973.
30. Ha, L., Merlino, G., and Sviderskaya, E.V. (2008). Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle 7, 1944-1948.
31. INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell 7, 733-745.
32. Halaban, R., Ghosh, S., Duray, P., Kirkwood, J.M., and Lerner, A.B. (1986). Human melanocytes cultured from nevi and melanomas. J. Invest. Dermatol. 87, 95-101.
33. Herbig, U., and Sedivy, J.M. (2006). Regulation of growth arrest in senescence: telomere damage is not the end of the story. Mech. Ageing Dev. 127, 16-24.
34. Herlyn, M., Balaban, G., Bennicelli, J. et al. (1985a). Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J. Natl Cancer Inst. 74, 283-289.
35. Herlyn, M., Thurin, J., Balaban, G. et al. (1985b). Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 45, 5670-5676.
36. Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., and DePinho, R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20, 1218-1249.
37. Höglund, M., Gisselsson, D., Hansen, G.B., Säll, T., and Mitelman, F. (2003). Ovarian carcinoma develops through multiple modes of chromosomal evolution. Cancer Res. 63, 3378-3385.
38. Hsu, M.-Y., Elder, D.E., and Herlyn, M. (2000). Melanoma: the Wistar melanoma (WM) cell lines. in Human Cell Culture, vol. 3. J.R.W., Masters., and B., Palsson., eds. (London: Kluwer Academic Publishers), pp. 259-274.
39. Itahana, K., Zou, Y., Itahana, Y., Martinez, J.L., Beausejour, C., Jacobs, J.J., van Lohuizen, M., Band, V., Campisi, J., and Dimri, G.P. (2003). Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol. Cell. Biol. 23, 389-401.
40. Jacobs, J.J.L., and de Lange, T. (2005). p16INK4a as a second effector of the telomere damage pathway. Cell Cycle 4, 1364-1368.
41. Keith, W.N., and Hoare, S.F. (2004). Detection of telomerase hTERT gene expression and its splice variants by RT-PCR. Methods Mol. Med. 97, 297-309.
42. INK4 in benign and malignant melanocytic lesions. J. Invest. Dermatol. 110, 932-938.
43. Khodadoust, M.S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J.C., Kim, D.S., Chinnaiyan, A.M., Markovitz, D.M., and Soengas, M.S. (2009). Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res. 69, 6405-6413.
44. Kobayashi, H., Man, S., MacDougall, J.R., Graham, C.H., Lu, C., and Kerbel, R.S. (1994). Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype. Am. J. Pathol. 144, 776-786.
45. Mancianti, M.L., Herlyn, M., Weil, D., Jambrosic, J., Rodeck, U., Becker, D., Diamond, L., Clark, W.H., and Koprowski, H. (1988). Growth and phenotypic characteristics of human nevus cells in culture. J. Invest. Dermatol. 90, 134-141.
46. E600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720-724.
47. Mooi, W.J., and Krausz, T. (2007). Pathology of Melanocytic Disorders, 2 edn. (London: Hodder Arnold).
48. Mooi, W.J., and Peeper, D.S. (2002). Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence? Histopathology 41(Suppl. 2), 120-146.
49. Mooi, W.J., and Peeper, D.S. (2006). Oncogene-induced cell senescence - halting on the road to cancer. N. Engl. J. Med. 355, 1037-1046.
50. Narita, M., Nunez, S., Heard, E., Narita, M., Lin, A.W., Hearn, S.A., Spector, D.L., Hannon, G.J., and Lowe, S.W. (2003). Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703-716.
51. Newbold, R.F. (2002). The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis 17, 539-550.
52. Parrinello, S., Samper, E., Krtolica, A., Goldstein, J., Melov, S., and Campisi, J. (2003). Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 5, 741-747.
53. Peddibhotla, S., and Rosen, J.M. (2009). Chking and executing cell division to prevent genomic instability. Cell Cycle 8, 2339-2342.
54. Pope, J.H., Morrison, L., Moss, D.J., Parsons, P.G., and Mary, S.R. (1979). Human malignant melanoma cell lines. Pathology 11, 191-195.
55. Quintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and Morrison, S.J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
56. Quintana, E., Shackleton, M., Foster, H.R., Fullen, D.R., Sabel, M.S., Johnson, T.M., and Morrison, S.J. (2010). Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510-523.
57. Rudolph, P., Schubert, C., Tamm, S., Heidorn, K., Hauschild, A., Michalska, I., Majewski, S., Krupp, G., Jablonska, S., and Parwaresch, R. (2000). Telomerase activity in melanocytic lesions: a potential marker of tumor biology. Am. J. Pathol. 156, 1425-1432.
58. Rudolph, K.L., Millard, M., Bosenberg, M.W., and DePinho, R.A. (2001). Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28, 155-159.
59. Semple, T.U., Moore, G.E., Morgan, R.T., Woods, L.K., and Quinn, L.A. (1982). Multiple cell lines from patients with malignant melanoma: morphology, karyology and biochemical analysis. J. Natl Cancer Inst. 68, 365-380.
60. INK4a. Cell 88, 593-602.
61. Seshadri, T., and Campisi, J. (1990). Repression of c-fos transcription and an altered genetic program in senescent human-fibroblasts. Science 247, 205-209.
62. Soo, J.K., MacKenzie Ross, A.D., and Bennett, D.C. (in press). Isolation and culture of melanoma and naevus cells and cell lines. Methods Mol. Biol. 731.
63. Stewart, S.A., and Weinberg, R.A. (2006). Telomeres: cancer to human aging. Annu. Rev. Cell Dev. Biol. 22, 531-557.
64. Ink4a in melanocyte senescence and differentiation. J. Natl Cancer Inst. 94, 446-454.
65. Sviderskaya, E.V., Gray-Schopfer, V.C., Hill, S.P. et al. (2003). p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J. Natl Cancer Inst. 95, 723-732.
66. INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int. J. Cancer 74, 255-259.
67. ARF in replicative and induced senescence of human fibroblasts. Mol. Cell. Biol. 21, 6748-6757.
68. Wynford-Thomas, D. (1999). Cellular senescence and cancer. J. Pathol. 187, 100-111.
69. Zakut, R., Perlis, R., Eliyahu, S., Yarden, Y., Givol, D., Lyman, S.D., and Halaban, R. (1993). KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 8, 2221-2229.